ArticleBiomolecules & biomedicine2026
HALP outperforms systemic inflammatory biomarkers for prognosis in locally advanced cervical cancer treated with concurrent chemoradiotherapy.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with locally advanced cervical cancer (LACC) treated with concurrent chemoradiotherapy (CCRT) show substantial heterogeneity in survival outcomes, whereas the comparative prognostic value of systemic inflammatory and nutritional biomarkers remains unclear. This study aimed to compare pretreatment inflammatory biomarkers, identify the most informative prognostic indicator, and develop a practical risk-stratification model for LACC. In this multicenter retrospective study, 290 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIB-IIIC cervical squamous cell carcinoma treated with definitive platinum-based CCRT followed by brachytherapy at two tertiary centers were analyzed. Twelve pretreatment inflammatory and nutritional indices, including the hemoglobin-albumin-lymphocyte-platelet (HALP) score, pan-immune-inflammation value (PIV), and neutrophil-to-lymphocyte ratio (NLR), were evaluated for overall survival (OS) and progression-free survival (PFS) using the concordance index (C-index), time-dependent area under the curve (AUC), and Brier score. Cox regression identified independent prognostic factors, and HALP-based nomograms were internally validated. Among all biomarkers, HALP showed the best and most stable prognostic performance for both OS and PFS, with the highest discrimination and lowest prediction error. Low HALP remained independently associated with worse OS and PFS in multivariable analysis (OS: hazard ratio [HR], 1.654; 95% confidence interval [CI], 1.165-2.366; PFS: HR, 1.702; 95% CI, 1.233-2.344). Nomograms integrating HALP, tumor size, and human papillomavirus (HPV) status showed good calibration and improved predictive accuracy beyond FIGO stage and the baseline clinical model. HALP may therefore serve as a robust, inexpensive, and clinically accessible biomarker for individualized risk stratification in LACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.